HAD protocol

consists of homoharringtonine, ara-C, and daunorubicin for the treatment of acute myeloid leukemia

Networked: 12 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - HAD protocol: 12
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - HAD protocol: 12
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - HAD protocol: 12
Heterocyclic Compounds: 198
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Cytidine: 535
      - Cytarabine: 6662
        HAD protocol: 12
  - Arabinonucleosides: 1
    - Cytarabine: 6662
      - HAD protocol: 12
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Anthracyclines: 9423
        Daunorubicin: 2641
        HAD protocol: 12
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        HAD protocol: 12
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        HAD protocol: 12

Experts

1.	Betof Warner, Allison: 1 article (01/2022)
2.	Callahan, Margaret K: 1 article (01/2022)
3.	Chapman, Paul B: 1 article (01/2022)
4.	Cugliari, Marina K: 1 article (01/2022)
5.	Eton, Omar: 1 article (01/2022)
6.	Goldman, Debra A: 1 article (01/2022)
7.	Momtaz, Parisa: 1 article (01/2022)
8.	Nair, Suresh G: 1 article (01/2022)
9.	Naito, Ellesa: 1 article (01/2022)
10.	Panageas, Katherine S: 1 article (01/2022)

Related Diseases

1.	Infections 09/01/1998 - "The primary purpose of the clinical trial was to assess the safety and efficacy of once-a-day compared with three-times-a-day gentamicin in patients with serious infections who had protocol-determined peak serum aminoglycoside concentrations. "
2.	Hemorrhage 06/01/2018 - "The median annualised index joint bleeding rate was 0·95 per year (IQR 0·44-1·35; range 0·00-13·43), but 17 (30%) patients had protocol-defined unacceptable breakthrough bleeding at some point during the study. " 08/01/2021 - "Nearly two-thirds of patients with major bleeding associated with direct oral anticoagulant administration had protocol deviation, but there was no effect on mortality."
3.	Atherosclerosis 11/01/1992 - "In a separate study, the relation of DHEAS levels to extent of atherosclerosis was examined among 82 cohort men who died during the follow-up period and had protocol autopsies. "
4.	Metrorrhagia (Spotting) 06/01/2018 - "The median annualised index joint bleeding rate was 0·95 per year (IQR 0·44-1·35; range 0·00-13·43), but 17 (30%) patients had protocol-defined unacceptable breakthrough bleeding at some point during the study. "
5.	Prostatic Neoplasms (Prostate Cancer) 01/01/2019 - "The primary outcome was the detection of clinically significant prostate cancer of International Society of Urological Pathology grade group 2 or higher (csPCa-A), analysed in all patients who received both systematic and targeted biopsies and whose results from both were available for pathological central review, including patients who had protocol deviations. " 09/01/2011 - "After 8 years, 8 patients had protocol-defined biochemical (prostate-specific antigen) failure (cumulative incidence, 8.0%); 5 patients had local failure (cumulative incidence, 5.5%); and 1 patient had distant failure (cumulative incidence, 1.1%; this patient also had biochemical failure and died of causes not related to prostate cancer). "

Related Drugs and Biologics

1.	Gentamicins (Gentamicin)
2.	Aminoglycosides
3.	Prostate-Specific Antigen (Semenogelase)
4.	Glucose (Dextrose)
5.	Anticoagulants

Related Therapies and Procedures

1.	Sutures (Suture)